Search - tctmd.com

Displaying 61 - 80 of 159

Sort: Relevancy | Date

Presentation TCT Abstracts Posters 2018

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

Presenter: Hyungdon Kook

September 25, 2018

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

Presenter: Mitchell W. Krucoff

September 22, 2018

Presentation TCT 2018

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Sorin J. Brener

September 22, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation JIM 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presenter: Roxana Mehran

February 23, 2018

Presentation TCT 2017

TCT 76: Impact of Post-Discharge Dual Antiplatelet Therapy vs Aspirin Alone After CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Presenter: Thomas H. Maloney, C. Michael Gibson

October 30, 2017

Presentation JIM 2017

The COMBO Plus Dual Therapy Stent: Clinical Update and Experience

Presenter: Gennaro Sardella

February 09, 2017

Presentation TCT 2016

TCT 66: Effects of Dual Antiplatelet Therapy Cessation Among Patients With Diabetes Mellitus After PCI With DES

Presenter: Sorin J. Brener, Jean-François Tanguay, Michela Faggioni

October 31, 2016

Presentation TCT 2016

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi

October 31, 2016

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

Presentation JIM 2016

The COMBO dual therapy stent: From the REMEDEE registry to the REDUCE trial

Presenter: Giuseppe De Luca

February 10, 2016

Presentation

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Presenter: Dean J. Kereiakes

October 22, 2015

Presentation TCT 2015

TCT 82: Single Versus Dual Antiplatelet Therapy in Transcatheter Aortic Valve Replacement A Meta-analysis of Safety and Efficacy Outcomes

Presenter: Lisa K. Jennings, Neal S. Kleiman, Rhanderson Cardoso

October 13, 2015

Presentation TCT 2015

TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Yaling Han

October 13, 2015

Presentation TCT 2015

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Bo Xu

October 13, 2015

Presentation TCT 2015

PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy?

Presenter: George D. Dangas, Paul A. Gurbel, C. Michael Gibson

October 13, 2015

Advertisement

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

TCT 76: Impact of Post-Discharge Dual Antiplatelet Therapy vs Aspirin Alone After CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

The COMBO Plus Dual Therapy Stent: Clinical Update and Experience

TCT 66: Effects of Dual Antiplatelet Therapy Cessation Among Patients With Diabetes Mellitus After PCI With DES

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

The COMBO dual therapy stent: From the REMEDEE registry to the REDUCE trial

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

TCT 82: Single Versus Dual Antiplatelet Therapy in Transcatheter Aortic Valve Replacement A Meta-analysis of Safety and Efficacy Outcomes

TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content